Need Help? Contact Us.

Enquire now

SARS-CoV-2 S1-RBD IgG

Product Description

The IDS SARS-CoV-2 S1-RBD IgG assay uses chemiluminescence immunoassay (CLIA) technology for semi-quantitative determination of specific IgG antibodies to S1 subunit in human serum samples on the IDS system.

The results are intended to assist the clinician in the diagnosis of SARS-CoV-2 infection, in evaluating immune status of infected individuals, and to monitor antibody response in individuals that have received the COVID-19 vaccine.

  • Confidence in the results
  • Applicable for Natural infection monitoring or antibody response level after vaccination follow-up
  • Traceable to the 1st WHO International Standard Anti-SARS-CoV-2 Immunoglobulin (Human), code NIBSC 20/136 for SARS-CoV-2 S1-RBD IgG
  • Good correlation with on-market S1-RBD COVID-19 IgG assay
  • High sensitivity and specificity
  • Streamlined workflow, rapid results and cost effective
  • Ready to use, 100 test reagent cartridges with convenient on-board stability for up to 60 days
  • Calibrate once every 21 days
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382: 727-733. doi:10.1056/NEJMoa2001017
    2. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 16-24 February 2020
    3. Chen B, Tian E-K, He B, et al. Overview of lethal human coronaviruses. Signal Transduct Target Ther 2020;5(1):89. doi:10.1038/s41392-020-0190-2
    4. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med 2020;26(7):1033-1036. doi:10.1038/s41591-020-0913-5
    5. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396(10249):467-478. doi:10.1016/S0140-6736(20)31604-4

Add to Enquiry Basket

SARS-CoV-2 S1-RBD IgG

Quantity

Related Products

This site is registered on wpml.org as a development site.